Investigational drug · Phase 3
Equecabtagene Autoleucel
Also called: FUCASO
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Refractory Immune-mediated Necrotizing Myopathy, Multiple Myeloma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "Equecabtagene Autoleucel"
First trial start
2024
Mar 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Equecabtagene Autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Immune-mediated Necrotizing Myopathy
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Equecabtagene Autoleucel" as an intervention, largest first.
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Pivotal-lookingActive, not recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT06464991 · 260 participants (planned) · Start Mar 27, 2024 · Primary completion Aug 2027
Drug: Equecabtagene Autoleucel Injection; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Beijing, China; Changchun, China; Chengdu, China · 41 sites in all
- A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Not yet recruiting
Peking University People's HospitalAcademic, hospital or other
NCT06369935 · 260 participants (planned) · Start Jun 20, 2024 · Primary completion Aug 20, 2026
Drug: Equecabtagene Autoleucel · For: Relapsed/Refractory Multiple Myeloma
Sites: Beijing, China
- A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing MyopathyNot yet recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07752264 · 27 participants (planned) · Start Aug 15, 2026 · Primary completion Aug 15, 2030
Drug: Equecabtagene Autoleucel Injection (Eque-cel) · For: Refractory Immune-mediated Necrotizing Myopathy
Sites: Beijing, China; Zhengzhou, China; Shanghai, China · 4 sites in all
- A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell LeukemiaActive, not recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT05870917 · 25 participants · Start May 23, 2023 · Primary completion Sep 18, 2025
Drug: anti-BCMA CAR-T; VRD-based Regimen · For: Plasma Cell Leukemia
Sites: Tianjin, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT05979363 · 20 participants (planned) · Start Aug 14, 2023 · Primary completion Dec 1, 2026
Drug: anti-BCMA CAR-T; VRD-based regimen · For: Plasma Cell Leukemia
Sites: Tianjin, China
- Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL AmyloidosisNot yet recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07055724 · 17 participants (planned) · Start Jul 2025 · Primary completion Jun 2027
Drug: Eque-cel CAR-T Therapy · For: AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07510100 · 17 participants (planned) · Start May 10, 2026 · Primary completion Aug 31, 2029
Drug: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel) · For: Relapsed/Refractory Multiple Myeloma
Sites: Bunkyo-ku, Japan; Shibuya-ku, Japan; tabashi City, Japan
Tongji HospitalAcademic, hospital or other
NCT06902844 · 6 participants (planned) · Start Apr 5, 2025 · Primary completion Oct 31, 2027
Drug: Equecabtagene Autoleucel Injection · For: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN)
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report.
Zhang R, Cheng L, Liu J, et al. · Exp Ther Med 2026
- Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report.
Wang Y, Cao Q, Jia Y, et al. · Front Med (Lausanne) 2026
- BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report.
Han H, Zhao D, Li A, et al. · Ann Hematol 2026
- Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.
Song Z, Fu Q, Du J · Hematol Oncol 2026
- Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.
Zhou L, Cheng PNM, Mi JQ · Front Immunol 2025
- Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma.
An N, Li J, Luo P, et al. · J Transl Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.